Lactobacillus Paracasei subsp. Paracasei F19: a farmacogenomic and clinical update

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Introduction: Many reports in literature have underlined particular features of Lactobacillus paracasei subsp paracasei F19, however a critical review of main clinical outcomes has not been performed so far. Objectives: This review summarizes the most relevant reports, in terms of clinical benefits, of Lactobacillus paracasei subsp paracasei F19 administration reviewing it's historical background and outlining new interesting perspectives in clinical practice. Methods: We searched Pubmed/Medline using the terms "Lactobacillus paracasei subsp paracasei F19". All clinical and experimental articles on the use of Lactobacillus paracasei subsp paracasei F19 were included. Results and discussion: The genetic stability of F19, the most relevant clinical claim, renders it's administration reliable and effective in immunocompromised people. Adequate concentrations of this strain support a dose/effect strategy ranging between NF B host macrophage activation to pathogenic bacteria overgrowth control as well as to fine interaction with the gut nerve endings. Moreover preliminary results from our lab support the formulation of F19 encapsulated with lyophilized HA in patients with IBD due to both an increased mucous-strain adherence and a possible enhanced strain proliferation and maintenance. Conclusions: Further experiments are required to overcome the lack of informations about this new formulation for IBD management.

Translated abstract

Introducción: Muchas notificaciones en la bibliografía han puesto de manifiesto las características particulares del Lactobacillus paracasei, subespecie paracasei F19; sin embargo, la revisión crítica de los principales resultados clínicos aún no se ha realizado. Objetivos: Esta revisión resume los artículos más relevantes, en términos de beneficios clínicos, sobre administración del Lactobacillus paracasei, subespecie paracasei F19, revisando su historia y recalcando nuevas perspectivas interesantes sobre su uso en la práctica clínica. Métodos: realizamos una búsqueda en Pubmed/Medline usado los términos "Lactobacillus paracasei subsp paracasei F19". Se incluyeron todos los artículos experimentales que empleasen el Lactobacillus paracasei, subespecie paracasei F19. Resultados y discusión: La estabilidad genética de F19, su característica clínica más relevante, hace que su administración sea fiable y eficaz en personas inmunosuprimidas. Las concentraciones adecuadas de esta cepa apoyan una estrategia de dosis/efecto que varía entre la activación de los macrófagos del hospedador hasta un control del sobrecrecimiento de bacterias patógenas, así como una adecuada interacción con las terminaciones nerviosas intestinales. Además, los resultados preliminares de nuestro laboratorio apoyan la formulación encapsulada de Lactobacillus F19 con AH liofilizada en pacientes con EII debido a una mayor adherencia de la cepa a la mucosa y un posible favorecimiento de la proliferación y mantenimiento de la cepa. Conclusiones: Se necesitan experimentos adicionales para paliar el déficit de información acerca de esta nueva formulación para el tratamiento de la EII.

Related collections

Most cited references 97

Record: found
Abstract: found
Article: not found

A core gut microbiome in obese and lean twins

Peter J. Turnbaugh, Micah Hamady, Tanya Yatsunenko … (2008)

The human distal gut harbors a vast ensemble of microbes (the microbiota) that provide us with important metabolic capabilities, including the ability to extract energy from otherwise indigestible dietary polysaccharides1–6. Studies of a small number of unrelated, healthy adults have revealed substantial diversity in their gut communities, as measured by sequencing 16S rRNA genes6–8, yet how this diversity relates to function and to the rest of the genes in the collective genomes of the microbiota (the gut microbiome) remains obscure. Studies of lean and obese mice suggest that the gut microbiota affects energy balance by influencing the efficiency of calorie harvest from the diet, and how this harvested energy is utilized and stored3–5. To address the question of how host genotype, environmental exposures, and host adiposity influence the gut microbiome, we have characterized the fecal microbial communities of adult female monozygotic and dizygotic twin pairs concordant for leanness or obesity, and their mothers. Analysis of 154 individuals yielded 9,920 near full-length and 1,937,461 partial bacterial 16S rRNA sequences, plus 2.14 gigabases from their microbiomes. The results reveal that the human gut microbiome is shared among family members, but that each person’s gut microbial community varies in the specific bacterial lineages present, with a comparable degree of co-variation between adult monozygotic and dizygotic twin pairs. However, there was a wide array of shared microbial genes among sampled individuals, comprising an extensive, identifiable ‘core microbiome’ at the gene, rather than at the organismal lineage level. Obesity is associated with phylum-level changes in the microbiota, reduced bacterial diversity, and altered representation of bacterial genes and metabolic pathways. These results demonstrate that a diversity of organismal assemblages can nonetheless yield a core microbiome at a functional level, and that deviations from this core are associated with different physiologic states (obese versus lean).

0 comments Cited 1270 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model.

R D Berg, A W Garlington (1979)

Viable bacteria were not cultured from the mesenteric lymph nodes, spleens, or livers of specific-pathogen-free (SPF) mice. Viable enteric bacteria, primarily indigenous Escherichia coli and lactobacilli, were present in the mesenteric lymph nodes of gnotobiotic mice inoculated intragastrically with the whole cecal microflora from SPF mice but not in the nodes of control SPF mice similarly inoculated. These indigenous E. coli also were cultured from the mesenteric lymph nodes of 96% of gnotobiotic mice monoassociated with E. coli but from none of the mesenteric lymph nodes of SPF mice inoculated with the E. coli. Furthermore, viable E. coli were detected in the mesenteric lymph nodes of these monoassociated gnotobiotes for as long as 112 days after inoculation. Indigenous Lactobacillus acidophilus also translocated to the mesenteric lymph nodes of gnotobiotic mice monoassociated with L. acidophilus. Apparently, there are mechanisms active in SPF mice inhibiting translocation of indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes, spleens, and livers, whereas these mechanisms are either absent or reduced in gnotobiotic mice. Indigenous E. coli maintained higher population levels in the gastrointestinal tracts of the gnotobiotes compared with their population levels in SPF mice, suggesting that high bacterial population levels might promote translocation of certain bacteria from the gastrointestinal lumen to the mesenteric lymph nodes. Gnotobiotic and SPF mice, therefore, provide experimental models for determining the nature of the mechanisms operating to confine indigenous bacteria to the gastrointestinal tract in normal, healthy animals.

0 comments Cited 109 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Decreased Fat Storage by Lactobacillus Paracasei Is Associated with Increased Levels of Angiopoietin-Like 4 Protein (ANGPTL4)

Linda Aronsson, Ying Huang, Paolo Parini … (2010)

Background Intervention strategies for obesity are global issues that require immediate attention. One approach is to exploit the growing consensus that beneficial gut microbiota could be of use in intervention regimes. Our objective was to determine the mechanism by which the probiotic bacteria Lactobacillus paracasei ssp paracasei F19 (F19) could alter fat storage. Angiopoietin-like 4 (ANGPTL4) is a circulating lipoprotein lipase (LPL) inhibitor that controls triglyceride deposition into adipocytes and has been reported to be regulated by gut microbes. Methodology/Principal Findings A diet intervention study of mice fed high-fat chow supplemented with F19 was carried out to study potential mechanistic effects on fat storage. Mice given F19 displayed significantly less body fat, as assessed by magnetic resonance imaging, and a changed lipoprotein profile. Given that previous studies on fat storage have identified ANGPTL4 as an effector, we also investigated circulating levels of ANGPTL4, which proved to be higher in the F19-treated group. This increase, together with total body fat and triglyceride levels told a story of inhibited LPL action through ANGPTL4 leading to decreased fat storage. Co-culture experiments of colonic cell lines and F19 were set up in order to monitor any ensuing alterations in ANGPTL4 expression by qPCR. We observed that potentially secreted factors from F19 can induce ANGPTL4 gene expression, acting in part through the peroxisome proliferator activated receptors alpha and gamma. To prove validity of in vitro findings, germ-free mice were monocolonized with F19. Here we again found changes in serum triglycerides as well as ANGPTL4 in response to F19. Conclusions/Significance Our results provide an interesting mechanism whereby modifying ANGPTL4, a central player in fat storage regulation, through manipulating gut flora could be an important gateway upon which intervention trials of weight management can be based.